Policy & Regulation
Vitruvias Therapeutics Enters into a Semi-Solid (Topical) Licensing Agreement with Hong Kong-Based Bright Future
11 February 2019 - - Alabama, US-based finished-dose generic drug company Vitruvias Therapeutics Inc. has entered into a collaborative development agreement with Hong Kong-based pharmaceutical company Bright Future Pharmaceutical Lab Ltd to develop a portfolio of semi-solids to be marketed in the United States and China, the company said.

US distribution will be handled by Vitruvias and Bright Future will be responsible for China and other agreed upon Asian territories.

The products will be manufactured by Bright Future's newly constructed unit at its Hong Kong site specifically designed for producing products in regulated markets.

Vitruvias Therapeutics is a generic pharmaceutical company which utilises domestic and international partnerships to develop, manufacture, and market generic products.

Founded in the southern US in 2013, the company's primary focus is on products in the generic sterile injectable market, semi-solid market, and selected high-value oral solids.

The company currently markets several generic products in the US The company received its first approval in September 2017 and anticipates several additional ANDA applications will be filed during 2019. 

Headquartered in Hong Kong, Bright Future Group is a leading pharmaceutical company committed to developing generic medical solutions since 1993.

Currently, the company is the largest PIC/S GMP certified pharmaceutical manufacturer in Hong Kong.

With years of development, it has also established subsidiary plants in Hong Kong, Mainland China, the USA and Germany.

Pursuing its long-term corporate vision, 7,000 employees dedicate themselves to the research and development, manufacturing and commercialization of generic medicines, health supplements and daily necessities worldwide.

It focuses on the treatment of disorders for patients in the areas of dermatology, orthopedics, respiratory, pediatrics, geriatric and gynecology.

Bright Future Group has international R and D teams in Hong Kong, New York, as well as Haikou and Suzhou in China to support its network.